<DOC>
	<DOCNO>NCT01155258</DOCNO>
	<brief_summary>RATIONALE : Temsirolimus may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , vinorelbine ditartrate , work different way stop growth tumor cell , either kill cell stop divide . Giving temsirolimus together vinorelbine ditartrate may kill tumor cell . PURPOSE : This phase I trial study side effect best dose give temsirolimus vinorelbine ditartrate together treat patient unresectable metastatic solid tumor .</brief_summary>
	<brief_title>Temsirolimus Vinorelbine Ditartrate Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximal tolerate dose ( MTD ) combination temsirolimus vinorelbine advance solid tumor . II . To obtain preliminary information regard activity combination . SECONDARY OBJECTIVES : I . To evaluate safety tolerability combination . OUTLINE : Patients receive temsirolimus IV 30-60 minute day 1 , 8 , 15 , 22 vinorelbine ditartrate IV 5-10 minute day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>Carcinoma , Islet Cell</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Medullary</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Patients histologically confirm metastatic unresectable solid tumor standard curative measure exist longer effective ; histology limit tumor temsirolimus vinorelbine report clinical activity : lung , breast , ovary , cervix , prostate , uterus , renal , bladder neuroendocrine tumor SWOG performance status 02 Projected life expectancy least 3 month Provision inform consent prior studyrelated procedure Negative pregnancy test woman childbearing potential Female patient must pregnant due potential mutagenicity teratogenicity treatment ; pregnancy test must administer 7 day prior administration therapy woman childbearing potential ; patient must agree use form contraception study initiation duration participation study ; sexually active male must also use reliable appropriate method contraception ; postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Patients must recover acute toxicity previous surgery , chemotherapy radiation therapy ANC &gt; = 1500/mm^3 Platelet count &gt; = 100,000 cells/mm^3 Hemoglobin &gt; = 9.0g/dL Serum creatinine = &lt; 1.5 mg/dl Hepatic function : Patients must adequate liver function : AST ALT = &lt; 2.5 X upper limit normal ( ULN ) , alkaline phosphatase = &lt; 2.5 X upper limit normal ; patient bone metastasis evidence liver metastasis bilirubin = &lt; upper limit normal alkaline phosphatase = &lt; 5 ULN allow Serum Bilirubin = &lt; 1.0 mg/dL Peripheral neuropathy grade 01 No concomitant therapy direct cancer allow Exclusion Prior therapy vinorelbine mTor inhibitor Receipt investigational agent within 30 day prior commence study treatment Last dose prior chemotherapy discontinue less 4 week start study therapy Last radiation therapy within last 4 week start study therapy , except palliative radiotherapy Any unresolved toxicity great CTC grade 1 previous anticancer therapy , exclude alopecia CTC Grade 1 great neuropathy ( motor sensory ) study entry Hematologic function absolute neutrophil = &lt; 1500/mm^3 and/or platelet &lt; 100,000/mm^3 Hepatic function serum bilirubin great upper institutional limit normal , ALT AST &gt; 2.5 time upper institutional limit normal Concurrent use strong inhibitor CYP3A4 : ketoconazole , itraconazole , ritonavir , amprenavir , indinavir , nelfinavir , delavirdine voriconazole CYP3A4 inducer avoid used caution ; use agent discourage : rifabutin , rifampicin , rifapentine , carbamazepine , Phenobarbital , phenytoin St. John 's wart Ongoing long term use steroid chronic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>